Table 3:
Notable Recent Trials in Non-Clear Cell Renal Cell Carcinoma
| Immune Checkpoint Inhibitors | |||||||
|---|---|---|---|---|---|---|---|
| Histology | |||||||
| Study | Treatment Agent | N | Papillary | Chromophobe | Other | Sarcomatoid* | ORR |
| KEYNOTE 427 | Pembrolizumab | 165 | 72% | 13% | 16% | 23% | 27% |
| CheckMate 374 | Nivolumab | 44 | 55% | 16% | 30% | 9% | 14% |
| MET Pathway Inhibitors | |||||||
| Histology | |||||||
| Study | Treatment Agent | N | Papillary | Chromophobe | Other | Sarcomatoid* | ORR |
| PAPMET (SWOG 1500) | Cabozantinib, Crizotinib, Savolitnib vs. Sunitinib | 152 | 100% | 0% | 0% | 0% | Cabozantinib 23%, Crizotinib 0%, Savolitinib 3%, Sunitinib 4% |
| SAVIOUR | Savolinitinib vs. Sunitinib | 60 | 100% | 0% | 0% | 0% | Savolinitib 27%, Sunitinib 7% |
ORR = objective response rate;
*
Sarcomatoid features can be found in any histologic subtype and are described distinctly from other histologic subtypes